Cellectar Biosciences Inc (CLRB)
3.25
+0.09
(+2.85%)
USD |
NASDAQ |
May 21, 16:00
3.25
0.00 (0.00%)
After-Hours: 20:00
Cellectar Biosciences Free Cash Flow (Quarterly): -13.38M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -13.38M |
December 31, 2023 | -9.862M |
September 30, 2023 | -8.665M |
June 30, 2023 | -7.530M |
March 31, 2023 | -7.184M |
December 31, 2022 | -7.530M |
September 30, 2022 | -7.020M |
June 30, 2022 | -5.829M |
March 31, 2022 | -5.070M |
December 31, 2021 | -4.641M |
September 30, 2021 | -6.433M |
June 30, 2021 | -6.884M |
March 31, 2021 | -4.753M |
December 31, 2020 | -3.886M |
September 30, 2020 | -3.502M |
June 30, 2020 | -3.084M |
March 31, 2020 | -3.523M |
December 31, 2019 | -2.687M |
September 30, 2019 | -3.548M |
June 30, 2019 | -2.662M |
March 31, 2019 | -2.822M |
December 31, 2018 | -3.127M |
September 30, 2018 | -2.969M |
June 30, 2018 | -2.546M |
March 31, 2018 | -3.186M |
Date | Value |
---|---|
December 31, 2017 | -2.826M |
September 30, 2017 | -2.569M |
June 30, 2017 | -2.918M |
March 31, 2017 | -3.054M |
December 31, 2016 | -2.416M |
September 30, 2016 | -2.215M |
June 30, 2016 | -1.906M |
March 31, 2016 | -1.818M |
December 31, 2015 | -1.513M |
September 30, 2015 | -2.171M |
June 30, 2015 | -2.196M |
March 31, 2015 | -2.392M |
December 31, 2014 | -2.153M |
September 30, 2014 | -2.099M |
June 30, 2014 | -2.008M |
March 31, 2014 | -2.610M |
December 31, 2013 | -2.692M |
September 30, 2013 | -2.595M |
June 30, 2013 | -2.034M |
March 31, 2013 | -1.982M |
December 31, 2012 | -1.754M |
September 30, 2012 | -1.699M |
June 30, 2012 | -1.512M |
March 31, 2012 | -1.718M |
December 31, 2011 | -1.542M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-13.38M
Minimum
Mar 2024
-2.662M
Maximum
Jun 2019
-5.884M
Average
-5.449M
Median
Free Cash Flow (Quarterly) Benchmarks
Perspective Therapeutics Inc | 4.776M |
Eli Lilly and Co | 83.20M |
Actinium Pharmaceuticals Inc | -7.385M |
Bristol-Myers Squibb Co | 2.55B |
Altimmune Inc | -16.36M |